DEADLINE ALERT for AAN, MGPI, ALGN, CAN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
02 avr. 2020 12h00 HE | Law Offices of Howard G. Smith
BENSALEM, Pa., April 02, 2020 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
GPM Logo.jpg
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against of Aaron's, Inc. (AAN)
31 mars 2020 15h17 HE | Glancy Prongay & Murray LLP; Aaron’s, Inc.
LOS ANGELES, March 31, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 28, 2020 deadline to file a lead plaintiff motion in the class action...
Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS
07 mai 2019 07h30 HE | Biogen Inc.
Updated results support lower risk of PML with extended interval dosing (EID; approximately every six weeks) for TYSABRI® (natalizumab) in patients in a real-world setting New interim data further...
uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting
07 mai 2019 07h00 HE | uniQure Inc.
~ Data Show AMT-150 Able to Significantly Lower Mutant Ataxin-3 Protein in SCA3 Disease Model ~ ~ Provides Further Support of Proof-of-concept of Company’s Proprietary miQURE™ Gene Silencing...
Retrotope Announces RT001 Clinical Data Presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting
06 mai 2019 12h57 HE | Retrotope
LOS ALTOS, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today positive findings from an expanded access study of the company’s lead candidate, RT001, in a patient with LOTS, as...
Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)
01 mai 2019 16h30 HE | Biogen Inc.
Tofersen, an antisense oligonucleotide (ASO) that selectively targets the genetic driver of disease, is being studied for the potential treatment of ALS in adults with a confirmed superoxide dismutase...
Summit Master_rgb_png.png
Summit Therapeutics Selected for Emerging Science Presentation at the 2018 American Academy of Neurology Annual Meeting
28 mars 2018 07h00 HE | Summit Therapeutics plc
OXFORD, United Kingdom and CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces that it has been selected for an Emerging Science dual oral...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Aaron’s, Inc. – AAN
28 juil. 2017 21h19 HE | The Rosen Law Firm PA
NEW YORK, July 28, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Aaron’s,...
MDA, AAN and ABF Awa
MDA, AAN and ABF Award Clinical Research Training Fellowship for Muscular Dystrophy
14 juil. 2017 11h04 HE | Muscular Dystrophy Association
Chicago, IL, July 14, 2017 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), together with the American Academy of Neurology (AAN) and the American Brain Foundation (ABF), is pleased to...
Adamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson’s Disease
24 avr. 2017 09h06 HE | Adamas Pharmaceuticals, Inc.
-- Results presented in oral platform and poster sessions at the 69th American Academy of Neurology (AAN) Annual Meeting -- -- Results from the pooled analysis showed approximately twice as many...